Figure 6.

Change from baseline in serum or plasma lipids at week 48. ^an = number of participants with nonmissing fasting lipid data at baseline and week 48, removing those with lipid-modifying agent administered at baseline (lipid data collected after initiation of a lipid-modifying agent were censored and a last observation carried forward method was applied so that the last available fasted, on-treatment lipid value before initiation of a lipid-modifying agent was used). ^bPercent change from baseline based on adjusted ratio (week 48 to baseline) in each group calculated from a repeated measures model applied to change from baseline in log_e-transformed data adjusting for the following: treatment, visit, baseline third agent class, CD4+ cell count (continuous), log_e-transformed baseline value (continuous), treatment-by-visit interaction, and baseline value-by-visit interaction, with visit as the repeated factor. *P = .017. **P < .001. Abbreviations: 3TC, lamivudine; DTG, dolutegravir; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TAF, tenofovir alafenamide.